Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 105 of the 106 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A growing body of evidence has suggested that metformin potentially reduces the risk of cancer. Our objective was to enhance the precision of estimates of the effect of metformin on the risk of any-site and site-specific cancers in patients with diabetes. METHODS/PRINCIPAL FINDINGS: We performed a search of MEDLINE, EMBASE, ISI Web of Science, Cochrane Library, and ClinicalTrials.gov for pertinent articles published as of October 12, 2011, and included them in a systematic review and meta-analysis. We calculated pooled risk ratios (RRs) for overall cancer mortality and cancer incidence. Of the 21,195 diabetic patients reported in 6 studies (4 cohort studies, 2 RCTs), 991 (4.5%) cases of death from cancer were reported. A total of 11,117 (5.3%) cases of incident cancer at any site were reported among 210,892 patients in 10 studies (2 RCTs, 6 cohort studies, 2 case-control studies). The risks of cancer among metformin users were significantly lower than those among non-metformin users: the pooled RRs (95% confidence interval) were 0.66 (0.49-0.88) for cancer mortality, 0.67 (0.53-0.85) for all-cancer incidence, 0.68 (0.53-0.88) for colorectal cancer (n = 6), 0.20 (0.07-0.59) for hepatocellular cancer (n = 4), 0.67 (0.45-0.99) for lung cancer (n = 3). CONCLUSION/SIGNIFICANCE: The use of metformin in diabetic patients was associated with significantly lower risks of cancer mortality and incidence. However, this analysis is mainly based on observational studies and our findings underscore the more need for long-term RCTs to confirm this potential benefit for individuals with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin may also confer a decreased cancer risk in patients with diabetes (90).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“All the procedures were in accordance with the guidelines for the Quality of Reporting of Meta-analyses [24], the meta-analysis of observational studies in epidemiology [25] and the PRISMA statement [26].”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.008 · Cited by 17,893
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630 · cited 1×
“In light of the fact that cancer is the second and diabetes the twelfth leading cause of death worldwide [59] and that the number of people with diabetes is”
Background
Cited by
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
ROS signalling in the biology of cancer
Moloney, J. N., & Cotter, T. G. (2018) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.05.023 · Cited by 1,970
The hallmarks of cancer metabolism: still emerging
Pavlova, N. N., Zhu, J., & Thompson, C. B. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.01.007 · Cited by 1,418
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
“Furthermore, retrospective clinical studies have found that metformin use is associated with improved cancer outcomes, reductions in cancer incidence, and decreased cancer mortality (Evans et al., 2005; Franciosi et al., 2013; Gandini et al., 2014; Lee et al., 2012; Noto et al., 2012).”
BackgroundMitochondrial reactive oxygen species and cancer
Sullivan, L. B., & Chandel, N. S. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-17 · Cited by 786
“drug metformin have recently been shown to have a reduced risk of cancer incidence and mortality [101].”
BackgroundUpdate on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“In different meta-analyses in T2DM patients, use of metformin compared with non-use or with use of other diabetes treatment, was related with a reduced risk of all cancers and lower cancer mortality [69,70] .”
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Immune-mediated antitumor effect by type 2 diabetes drug, metformin
Eikawa, S., Nishida, M., Mizukami, S., Yamazaki, C., Nakayama, E., & Udono, H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417636112 · Cited by 557
“Two independent metaanalyses of epidemiological studies concluded that compared with other treatments, metformin is associated with a 30–40% reduction in the incidence of cancer among patients with type 2 diabetes, indicating the need to investigate the anticancer mechanisms of metformin and conduct long-term randomiz…”
BackgroundHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Metformin and the Risk of Cancer
Suissa, S., & Azoulay, L. (2012) · Diabetes Care · doi:10.2337/dc12-0788 · Cited by 531
“Two metaanalyses including some of these observational studies reported a highly significant reduction in cancer incidence or mortality associated with metformin use (risk reductions ranged between 31 and 34%) (9,10).”
BackgroundInvestigating Metformin for Cancer Prevention and Treatment: The End of the Beginning
Pollak, M. N. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0263 · Cited by 507
Goto, A., Arah, O. A., Goto, M., Terauchi, Y., & Noda, M. (2013) · BMJ · doi:10.1136/bmj.f4533 · Cited by 492
Self-citationMolecular mechanism of action of metformin: old or new insights?
Rena, G., Pearson, E. R., & Sakamoto, K. (2013) · Diabetologia · doi:10.1007/s00125-013-2991-0 · Cited by 479
“In addition, there are likely to be other beneficial effects, including a reduction in cardiovascular disease and mortality compared with non-intensive treatment [4] and a possible reduction in cancer incidence, which has been seen in some [5–7], but not all [8], studies.”
ResultRisk factors for pancreatic cancer: a summary review of meta-analytical studies
Maisonneuve, P., & Lowenfels, A. B. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyu240 · Cited by 439
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Metformin and inflammation: its potential Beyond glucose-lowering effect
Saisho, Y. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150316124019 · Cited by 450
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428
“There have been 7 meta-analyses of existing studies of the association of metformin with different types of cancer in patients with diabetes [74-80].”
BackgroundMethodCellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
Palmer, A. K., Tchkonia, T., LeBrasseur, N. K., Chini, E. N., Xu, M., & Kirkland, J. L. (2015) · Diabetes · doi:10.2337/db14-1820 · Cited by 423
“Metformin may also confer a decreased cancer risk in patients with diabetes (90).”
BackgroundMetformin in cancer prevention and therapy.
Kasznicki, J., Śliwińska, A., & Drzewoski, J. (2014) · PubMed · doi:10.3978/j.issn.2305-5839.2014.06.01 · Cited by 316
“calculated pooled risk ratios (RRs) for overall cancer mortality and cancer incidence in 21,195 diabetic patients (48).”
BackgroundSaraei, P., Asadi, I., Kakar, M. A., & Moradi-Kor, N. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200059 · Cited by 350
“Noto et al studied risk ratio (RR) of 21,195 diabetic patients and reported a lower risk of developing cancers and deaths due to cancers among diabetic patients who used metformin to control their diabetes.(76) A recent study conducted by Libby et al on 8,000 T2DM patients suggested a lower incidence of cancer for tho…”
BackgroundEndoplasmic Reticulum Stress: Its Role in Disease and Novel Prospects for Therapy
Schönthal, A. H. (2012) · Scientifica · doi:10.6064/2012/857516 · Cited by 353
“Several biguanides (metformin, phenformin, and buformin) alsowere shown to belong to this group of GRP78 downregulators [177], which is intriguing in the context of metformin’s use as an antidiabetic medication [178] and its recently recognized potential for cancer risk reduction [179, 180].”
BackgroundCancer drug discovery by repurposing: teaching new tricks to old dogs
Gupta, S. C., Sung, B., Prasad, S., Webb, L. J., & Aggarwal, B. B. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.06.005 · Cited by 340
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.5 · Cited by 320
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.659 · Cited by 314
Repurposing metformin for the prevention of cancer and cancer recurrence
Heckman-Stoddard, B. M., DeCensi, A., Sahasrabuddhe, V. V., & Ford, L. G. (2017) · Diabetologia · doi:10.1007/s00125-017-4372-6 · Cited by 297
Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma
Curry, J. M., Sprandio, J., Cognetti, D., Luginbuhl, A., Bar-ad, V., Pribitkin, E., & Tuluc, M. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.03.003 · Cited by 293
Repositioning metformin for cancer prevention and treatment
Quinn, B. J., Kitagawa, H., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.05.004 · Cited by 281
AMP ‐activated protein kinase: a key regulator of energy balance with many roles in human disease
Grahame Hardie, D. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12268 · Cited by 285
Association of metformin use with cancer incidence and mortality: A meta-analysis
Zhang, P., Li, H., Tan, X., Chen, L., & Wang, S. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2012.12.009 · Cited by 270
Future directions in cancer prevention
Umar, A., Dunn, B. K., & Greenwald, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3397 · Cited by 248
Metformin and breast cancer risk: a meta-analysis and critical literature review
Col, N. F., Ochs, L., Springmann, V., Aragaki, A. K., & Chlebowski, R. T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2170-x · Cited by 216
“11 were excluded: three were systematic reviews of metformin and cancer risk in diabetic patients [10, 14, 15]; six did not report HR on breast cancer incidence but reported instead on overall cancer incidence [17–22]; one did not disaggregate metformin from insulin”
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Klil-Drori, A. J., Azoulay, L., & Pollak, M. N. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.120 · Cited by 210
Cruz-Bermúdez, A., Laza-Briviesca, R., Vicente-Blanco, R. J., García-Grande, A., Coronado, M. J., Laine-Menéndez, S., Palacios-Zambrano, S., Moreno-Villa, M. R., Ruiz-Valdepeñas, A. M., Lendinez, C., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.03.009 · Cited by 196
“Metformin has aroused great interest over the last years due to its association with lower cancer incidence in type two diabetic patients and better overall survival in cancer patients [14].”
BackgroundLessons from Mouse Models of High-Fat Diet-Induced NAFLD
Nakamura, A., & Terauchi, Y. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121240 · Cited by 186
“Epidemiological studies have shown that metformin treatment is associated with a significantly reduced risk of cancer mortality and development [60–62], and also that metformin significantly reduces the risk of development of liver cancer in humans [62–64].”
BackgroundPotential applications for biguanides in oncology
Pollak, M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67232 · Cited by 188
“2, 13, 14) provided retrospective evidence that diabetics treated with metformin have unexpectedly low incidence of cancer and/or reduced cancer mortality.”
Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects
Kamarudin, M. N. A., Sarker, M. M. R., Zhou, J.-R., & Parhar, I. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1495-2 · Cited by 191
Time‐related biases in pharmacoepidemiology
Suissa, S., & Dell'Aniello, S. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5083 · Cited by 173
Association of Diabetes Mellitus and Pancreatic Adenocarcinoma: A Meta-Analysis of 88 Studies
Batabyal, P., Vander Hoorn, S., Christophi, C., & Nikfarjam, M. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3625-6 · Cited by 183
Thakkar, B., Aronis, K. N., Vamvini, M. T., Shields, K., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.01.014 · Cited by 186
Driver, J. A. (2014) · Biogerontology · doi:10.1007/s10522-014-9523-2 · Cited by 182
“88) respectively (Noto et al. 2012).”
Wang, Z., Lai, S.-T., Xie, L., Zhao, J.-D., Ma, N.-Y., Zhu, J., Ren, Z.-G., & Jiang, G.-L. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.007 · Cited by 176
“[16] Noto H, Goto A, Tsujimoto T, Noda M.”
BackgroundScheen, A. J., & Paquot, N. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.02.006 · Cited by 174
Metformin Prevents Cisplatin-Induced Cognitive Impairment and Brain Damage in Mice
Zhou, W., Kavelaars, A., & Heijnen, C. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151890 · Cited by 165
The Links Between Insulin Resistance, Diabetes, and Cancer
Orgel, E., & Mittelman, S. D. (2013) · Current Diabetes Reports · doi:10.1007/s11892-012-0356-6 · Cited by 162
Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates
Gronich, N., & Rennert, G. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.169 · Cited by 161
Stevens, R. J., Ali, R., Bankhead, C. R., Bethel, M. A., Cairns, B. J., Camisasca, R. P., Crowe, F. L., Farmer, A. J., Harrison, S., Hirst, J. A., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2653-7 · Cited by 161
“Systematic reviews and meta-analyses that have examined cancer risk for metformin have emphasised the observational evidence, but included only three randomised trials [10, 11].”
BackgroundResultMetformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects
Emami Riedmaier, A., Fisel, P., Nies, A. T., Schaeffeler, E., & Schwab, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.11.005 · Cited by 161
Lung cancer chemoprevention: current status and future prospects
Keith, R. L., & Miller, Y. E. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.64 · Cited by 159
Yin, M., Zhou, J., Gorak, E. J., & Quddus, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0111 · Cited by 157
Rizos, C. V., & Elisaf, M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.038 · Cited by 169
Metformin and cancer: An existing drug for cancer prevention and therapy (Review)
Zi, F., Zi, H., Li, Y., He, J., Shi, Q., & Cai, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.7412 · Cited by 152
“Furthermore, Noto et al (74) revealed that the use of metformin in patients with diabetes may reduce the risk of cancer incidence and mortality, and indicated that analysis based upon observational studies and long-term randomized controlled trials should be performed to confirm this result.”
Kunisada, Y., Eikawa, S., Tomonobu, N., Domae, S., Uehara, T., Hori, S., Furusawa, Y., Hase, K., Sasaki, A., & Udono, H. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.10.009 · Cited by 149
“This is an open access article und compared with those taking other drugs (Evans et al., 2005; Morales and Morris, 2015; Noto et al., 2012).”
Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds
Würth, R., Thellung, S., Bajetto, A., Mazzanti, M., Florio, T., & Barbieri, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.017 · Cited by 167
New Perspective for an Old Antidiabetic Drug: Metformin as Anticancer Agent
Leone, A., Gennaro, E. D., Bruzzese, F., Avallone, A., & Budillon, A. (2013) · Cancer treatment and research · doi:10.1007/978-3-642-38007-5_21 · Cited by 161
“Metformin treatment decreased the risk of colon, lung, and liver cancers but did not affect the development of hormone-dependent prostate and breast cancers or of pancreatic or gastric cancers [61].”
BackgroundGlossmann, H. H., & Lutz, O. M. D. (2019) · Gerontology · doi:10.1159/000502257 · Cited by 149
Incio, J., Suboj, P., Chin, S. M., Vardam-Kaur, T., Liu, H., Hato, T., Babykutty, S., Chen, I., Deshpande, V., Jain, R. K., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0141392 · Cited by 144
Wu, L., Zhu, J., Prokop, L. J., & Murad, M. H. (2015) · Scientific Reports · doi:10.1038/srep10147 · Cited by 144
Mohammed, A., Janakiram, N. B., Brewer, M., Ritchie, R. L., Marya, A., Lightfoot, S., Steele, V. E., & Rao, C. V. (2013) · Translational Oncology · doi:10.1593/tlo.13556 · Cited by 142
“A recent analysis of a large pooled set of studies included in the National Cancer Institute Pancreatic Cancer Cohort Consortium has provided strong support for a positive association between obesity and increased risk of PC [9].”
BackgroundMetabolic requirements for cancer cell proliferation
Keibler, M. A., Wasylenko, T. M., Kelleher, J. K., Iliopoulos, O., Heiden, M. G. V., & Stephanopoulos, G. N. (2016) · Cancer & Metabolism · doi:10.1186/s40170-016-0156-6 · Cited by 158
“Diabetics taking metformin have a reduced incidence of cancer compared to diabetics that control blood sugar by other means, and a surge of investigations has followed to better understand its potential as a cancer therapeutic and its mechanism of action [61–66].”
BackgroundPillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
“Several reviews and meta-analysis suggests that taking drug 24 was associated with reduced risk of all cancer mortality in patients with diabetes [61] .”
BackgroundThe strange case of AMPK and cancer: Dr Jekyll or Mr Hyde?
Vara-Ciruelos, D., Russell, F. M., & Hardie, D. G. (2019) · Open Biology · doi:10.1098/rsob.190099 · Cited by 135
Sex and gender influences on pharmacological response: an overview
Franconi, F., & Campesi, I. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.922866 · Cited by 132
“Metformin improves the prognosis of breast cancer, raising the possibility of its use as an adjuvant treatment for breast cancer [242–245].”
BackgroundSurvival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin
Lin, J. J., Gallagher, E. J., Sigel, K., Mhango, G., Galsky, M. D., Smith, C. B., LeRoith, D., & Wisnivesky, J. P. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201407-1395oc · Cited by 137
“Metformin also appears to be associated with improved survival among diabetic patients with breast, prostate and colorectal cancer (14, 16, 17).”
Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony
Mirrakhimov, A. E. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-132 · Cited by 148
“Metformin may be beneficial in the prevention of cancer in general, in patients with type 2 DM and may in fact decrease mortality in patients with cancer and concomitant type 2 DM [219].”
BackgroundThe Potential Effect of Metformin on Cancer: An Umbrella Review
Yu, H., Zhong, X., Gao, P., Shi, J., Wu, Z., Guo, Z., Wang, Z., & Song, Y. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00617 · Cited by 135
Association between diabetes, diabetes treatment and risk of developing endometrial cancer
Luo, J., Beresford, S., Chen, C., Chlebowski, R., Garcia, L., Kuller, L., Regier, M., Wactawski-Wende, J., & Margolis, K. L. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.407 · Cited by 126
“Evidence from epidemiologic, clinical and experimental research has suggested that metformin may have potential anticancer effects (Evans et al, 2005; Buzzai et al, 2007; Ben Sahra et al, 2008; Decensi et al, 2010; Noto et al, 2012).”
BackgroundHursting, S. D., & Hursting, M. J. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.241927 · Cited by 132
Habib, S. L., & Rojna, M. (2013) · ISRN Oncology · doi:10.1155/2013/583786 · Cited by 143
“Besides lowering incidence rate, metformin was reported to diminish cancer mortality [128].”
BackgroundCancer—Incidence, prevalence and mortality in the oldest-old. A comprehensive review
Nolen, S. C., Evans, M. A., Fischer, A., Corrada, M. M., Kawas, C. H., & Bota, D. A. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.05.002 · Cited by 120
“Moreover, certain anti-diabetic drugs such as thiazolidinediones (Bosetti et al., 2013) and metformin (Noto et al., 2012) may also reduce the risk of all-site and type-speci fi c cancers like liver (Bosetti et al., 2013), colorectal (Bosetti et al., 2013; Noto et al., 2012), and lung cancer…”
InfluentialSingh, S., Singh, P. P., Singh, A. G., Murad, H. M., McWilliams, R. R., & Chari, S. T. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.7 · Cited by 123
Drug Repositioning for Effective Prostate Cancer Treatment
Turanlı, B., Grøtli, M., Borén, J., Nielsen, J., Uhlén, M., Arğa, K. Y., & Mardinoğlu, A. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00500 · Cited by 126
“Some studies supported the oncogenic benefit of metformin for PCa patients regardless their diabetic status (Noto et al., 2012), some of them emphasized heterogeneous and biased results or no significant effects on incidence of PCa (Margel et al., 2013).”
Giannoni, E., Taddei, M. L., Morandi, A., Comito, G., Calvani, M., Bianchini, F., Richichi, B., Raugei, G., Wong, N., Tang, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4448 · Cited by 119
“Recent clinical trials suggest that metformin could be effective in prostate cancer patients [42, 43], and it is possible that the ability of this drug to interfere with the metabolic circuitry between cancer and stromal cells is the basis of its efficiency.”
Probiotics for the management of type 2 diabetes mellitus: A systematic review and meta-analysis
Samah, S., Ramasamy, K., Lim, S. M., & Neoh, C. F. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.06.014 · Cited by 112
Association Between Metformin Therapy and Mortality After Breast Cancer
Lega, I. C., Austin, P. C., Gruneir, A., Goodwin, P. J., Rochon, P. A., & Lipscombe, L. L. (2013) · Diabetes Care · doi:10.2337/dc12-2535 · Cited by 110
“Recent evidence suggests that metformin may have antitumor effects (6).”
Allison, K. E., Coomber, B. L., & Bridle, B. W. (2017) · Immunology · doi:10.1111/imm.12777 · Cited by 109
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression
Duan, W., Chen, K., Jiang, Z., Chen, X., Sun, L., Li, J., Lei, J., Xu, Q., Ma, J., Li, X., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.019 · Cited by 106
Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies
Acton, E. K., Willis, A. W., & Hennessy, S. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5547 · Cited by 113
Kowall, B., Stang, A., Rathmann, W., & Kostev, K. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3823 · Cited by 100
“Patients were included into analyses based on the following criteria: (1) they had a diagnosis of diabetes; (2) they had at least 12months pre-history in the database prior to the first diabetes diagnosis; (3) they were 30–89years old at the time of diabetes diagnosis—so diabetes is most likely type 2 diabetes; (4) th…”
MethodDiabetes and Cancer—An AACE/ACE Consensus Statement
Handelsman, Y., LeRoith, D., Bloomgarden, Z. T., Dagogo-Jack, S. E., EINHORN, D. F., Garber, A. J., Grunberger, G., Harrell, R. M., Gagel, R. F., Lebovitz, H. E., et al. (2013) · Endocrine Practice · doi:10.4158/ep13248.cs · Cited by 105
“Other retrospective data point to decreased cancer incidence and mortality in metformin-treated patients (66,75-77).”
BackgroundInfluentialSkinner, H. D., Hu, C., Tsakiridis, T. K., Santana-Dávila, R., Lü, B., Erasmus, J. J., Doemer, A., Videtic, G. M. M., Coster, J. R., Yang, A. X., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2318 · Cited by 106
Diabetes mellitus and incidence and mortality of kidney cancer: A meta-analysis
Bao, C., Yang, X., Xu, W., Luo, H., Xu, Z., Su, C., & Qi, X. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.01.004 · Cited by 99
Singh, S., Singh, H., Singh, P. P., Murad, M. H., & Limburg, P. J. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0429 · Cited by 98
“In our study, the inclusion of more studies and simultaneous assessment of cancer-modifying effect of other ADM resulted in a lower risk estimate associated with metformin than has been reported in other meta-analyses.(20-22) Soranna et al estimated the association between metformin and sulfonylureas and risk of all-c…”
Sehdev, A., Shih, Y. T., Vekhter, B., Bissonnette, M. B., Olopade, O. I., & Polite, B. N. (2015) · Cancer · doi:10.1002/cncr.29165 · Cited by 96
MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities
Pedroza‐Torres, A., Romero-Cordoba, S. L., Justo-Garrido, M., Salido-Guadarrama, I., Rodríguez‐Bautista, R., Montaño, S., Muñiz-Mendoza, R., Arriaga-Canon, C., Fragoso‐Ontiveros, V., Álvarez-Gómez, R. M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01404 · Cited by 97
miRNA-Based Technologies in Cancer Therapy
Pagoni, M. N., Cava, C., Sideris, D. C., Avgeris, M., Zoumpourlis, V., Michalopoulos, I., & Drakoulis, N. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111586 · Cited by 100
Interventions for age-related diseases: Shifting the paradigm
Figueira, I., Fernandes, A., Mladenovic Djordjevic, A., Lopez-Contreras, A., Henriques, C. M., Selman, C., Ferreiro, E., Gonos, E. S., Trejo, J. L., Misra, J., et al. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.09.009 · Cited by 87
Old wine in new bottles: Drug repurposing in oncology
Antoszczak, M., Markowska, A., Markowska, J., & Huczyński, A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172784 · Cited by 94
Androgens and prostate cancer; pathogenesis and deprivation therapy
Grossmann, M., Cheung, A. S., & Zajac, J. D. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.001 · Cited by 97
Latest insights into the risk of cancer in diabetes
Noto, H., Goto, A., Tsujimoto, T., Osame, K., & Noda, M. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12068 · Cited by 88
Self-citationSyrosingopine sensitizes cancer cells to killing by metformin
Benjamin, D., Colombi, M., Hindupur, S. K., Betz, C., Lane, H. A., El-Shemerly, M. Y. M., Lu, M., Quagliata, L., Terracciano, L., Moes, S., et al. (2016) · Science Advances · doi:10.1126/sciadv.1601756 · Cited by 82
The Hallmarks of Cancer and the Radiation Oncologist: Updating the 5Rs of Radiobiology
Good, J., & Harrington, K. J. (2013) · Clinical Oncology · doi:10.1016/j.clon.2013.06.009 · Cited by 103
Effects of metformin on head and neck cancer: A systematic review
Rêgo, D. F., Pavan, L. M. C., Elias, S. T., Canto, G. D. L., & Guerra, E. N. S. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.01.007 · Cited by 91
Diabetes Mellitus and Risk of Hepatocellular Carcinoma
Li, X., Wang, X., & Gao, P. (2017) · BioMed Research International · doi:10.1155/2017/5202684 · Cited by 100
Cardiovascular Disease and Cancer: Is There Increasing Overlap?
Vincent, L. L., Leedy, D. J., Masri, S. C., & Cheng, R. K.-H. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0796-0 · Cited by 91
Luo, Q., Hu, D., Hu, S., Yan, M., Sun, Z., & Chen, F. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-517 · Cited by 90
“The use of metformin in diabetic patients was associated with significantly lower risks of cancer incidence and mortality [15].”
BackgroundMetformin use and gynecological cancers: A novel treatment option emerging from drug repositioning
Gadducci, A., Biglia, N., Tana, R., Cosio, S., & Gallo, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.06.006 · Cited by 91
“Several epidemiological studies and meta-analysis have shown that metformin use is associated with decreased cancer risk and /or reduced cancer mortality (3-14).”
BackgroundGuimarães, T. A., Farias, L. C., Santos, E. S., Fraga, C. A. D. C., Orsine, L. A., Teles, L. D. F., Feltenberger, J. D., de Jesus, S. F., de Souza, M. G., Santos, S. H. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10842 · Cited by 94
“The use of Metformin in diabetic patients is associated with a reduction in cancer incidence and mortality [26, 27].”
BackgroundPinyopornpanish, K., Leerapun, A., Pinyopornpanish, K., & Chattipakorn, N. (2021) · Gut and Liver · doi:10.5009/gnl20367 · Cited by 81
“Several epidemiological studies suggested that metformin had potential antitumor effect with potential effects in cancer prevention.(60,61) A large matched-paired cohort conducted in Taiwan found that metformin was associated with HCC incidence reduction in patients with T2DM with a hazard ratio of 0.”
Background
Metadata
- Authors
- Noto, H., Goto, A., Tsujimoto, T., & Noda, M.
- Affiliations
- National Center for Global Health and Medicine (JP)
- Corresponding author
- Noto, Hiroshi
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-20
- Volume
- 7
- Issue
- 3
- Pages
- e33411
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3308971
- OpenAlex
- W2040608814
- Cited by
- 566
- References
- 106
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 20 · 2023: 29 · 2022: 28 · 2021: 33 · 2020: 41 · 2019: 38 · 2018: 28 · 2017: 50 · 2016: 60 · 2015: 57 · 2014: 60 · 2013: 65 · 2012: 25
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Health, Labour and Welfare
- Japan Diabetes Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metformin, diabetes mellitus, cancer risk, cancer mortality, cancer incidence, colorectal cancer, hepatocellular carcinoma, lung cancer, chemoprevention
- MeSH terms
- Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Risk Factors, Meta-Analysis as Topic, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.